A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Grant

Date/time Interval

  • October 1, 2017 - September 30, 2022
  • Total Award Amount

  • 593008.00
  • Direct Costs

  • 456160.00
  • Sponsor Award Id

  • Contributor

  • Bhatia M.D., Ravi   Investigator  
  • Costa M.D., Ph.D., Luciano   Investigator  
  • Di Stasi M.D., Antonio   Principal Investigator  
  • Innis-Shelton M.D., Racquel   Investigator  
  • Salzman M.D., Donna   Investigator